Dateline City:
KENILWORTH, N.J.
KEYTRUDA Also Receives Breakthrough Therapy Designation for Second-Line Treatment Based on KEYNOTE-045, Which Includes Primary Endpoints of Overall Survival and Progression-Free Survival
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review two supplemental Biologics License Applications
(sBLAs) for KEYTRUDA (pembrolizumab), the companys
anti-PD-1 therapy, in patients with locally advanced or metastatic
urothelial cancer, a type of bladder cancer.
Language:
English
Contact:
For MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
@Merck
read more